Published in Diabet Med on August 16, 2015
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. PLoS Med (2016) 0.89
Infusion with Human Bone Marrow-derived Mesenchymal Stem Cells Improves β-cell Function in Patients and Non-obese Mice with Severe Diabetes. Sci Rep (2016) 0.76
Treg activation defect in type 1 diabetes: correction with TNFR2 agonism. Clin Transl Immunology (2016) 0.75
Type 1 Diabetes - A Clinical Perspective. Point Care (2017) 0.75
Rationale and protocol for the After Diabetes Diagnosis REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort study. BMJ Open (2017) 0.75
A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med (2004) 10.35
Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med (1986) 6.11
Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care (2003) 4.92
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Executive summary: Standards of medical care in diabetes--2014. Diabetes Care (2014) 2.59
Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care (1995) 2.49
Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care (2012) 2.45
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care (2008) 2.22
Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab (1987) 1.84
The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia (2014) 1.83
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One (2012) 1.74
Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41
Alternative markers of hyperglycemia and risk of diabetes. Diabetes Care (2012) 1.23
Complications of type 1 diabetes. Endocrinol Metab Clin North Am (2010) 1.18
The case for blood glucose control. Adv Intern Med (1995) 1.14
Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes (2013) 1.11
Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care (2014) 1.08
Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis (2011) 1.05
Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab (2012) 1.01
Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet Med (2012) 0.93
Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract (2013) 0.93
Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab (2013) 0.89
"Prediction is very hard, especially about the future": new biomarkers for type 2 diabetes? Diabetes (2013) 0.87
Relationship between serum 1,5-anhydroglucitol and urinary excretion of N-acetylglucosaminidase and albumin determined at onset of NIDDM with 3-year follow-up. Diabetes Care (1998) 0.86
Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care (2013) 0.83
Prevalence of residual B-cell function related to age at onset and genetic profile in newly diagnosed type I diabetics. Acta Diabetol Lat (1988) 0.77
Why were we wrong for so long? The pancreas of type 1 diabetic patients commonly functions for decades. Diabetologia (2013) 0.77
[The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically?]. Dtsch Med Wochenschr (1996) 1.44
Epidural adhesiolysis: an evidence-based review. J Neurosurg Sci (2014) 1.43
IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression. EMBO J (1989) 1.42
Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med (1994) 1.32
X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem (2000) 1.26
Relaxation-time and diffusion NMR microscopy of single neurons. J Magn Reson B (1994) 1.14
Is Xenopus IgX an analog of IgA? Eur J Immunol (1996) 1.11
A third immunoglobulin class in amphibians. J Immunol (1985) 1.07
What limits affinity maturation of antibodies in Xenopus--the rate of somatic mutation or the ability to select mutants? EMBO J (1992) 1.06
Reliability and validity of the objective structured clinical examination in paediatrics. Med Educ (1991) 1.04
Rearrangement of immunoglobulin genes in shark germ cells. J Exp Med (2000) 1.03
Improved detection of CFTR mutations in Southern California Hispanic CF patients. Hum Mutat (2001) 1.00
New approaches for studying the permeability of fish embryos: toward successful cryopreservation. Cryobiology (1997) 1.00
Major histocompatibility complex-encoded class I molecules are absent in immunologically competent Xenopus before metamorphosis. J Immunol (1986) 0.99
Studies on Xenopus immunoglobulins using monoclonal antibodies. Mol Immunol (1984) 0.98
Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. J Pediatr (1988) 0.95
Hemoglobin E: a common hemoglobinopathy among children of Southeast Asian origin. CMAJ (1987) 0.92
Changes in the immune system during metamorphosis of Xenopus. Immunol Today (1987) 0.92
A novel mutation in the CFTR gene correlates with severe clinical phenotype in seven Hispanic patients. J Med Genet (2000) 0.90
Medulloblastoma in children--the Ottawa experience. Childs Nerv Syst (2000) 0.90
Brain tumors in childhood and adolescence. Pediatr Neurol (1999) 0.90
A novel mutation detected by temporal temperature gradient gel electrophoresis led to the confirmative prenatal diagnosis of a Hispanic CF family. Prenat Diagn (2000) 0.89
Sequencing homopolymer tracts and repetitive elements. Biotechniques (1996) 0.88
Systemic lupus erythematosus and sickle hemoglobinopathies: a report of two cases and review of the literature. Am J Hematol (1987) 0.87
Effector and regulator functions of splenic and thymic lymphocytes in the clawed toad Xenopus. Ann Immunol (Paris) (1984) 0.87
Hardness and strength of endodontic instruments made from NiTi alloy. Aust Endod J (1998) 0.86
Anti-IgM treatment influences immunoglobulin heavy and light chain mRNA levels in mitogen-stimulated B lymphocytes. Eur J Immunol (1985) 0.86
Isolation and characterization of the Xenopus terminal deoxynucleotidyl transferase. J Immunol (1994) 0.84
Strategies to suppress aggregation of recombinant keratinocyte growth factor during liquid formulation development. J Pharm Sci (1994) 0.84
Evolution and somatic diversification of immunoglobulin light chains. Curr Top Microbiol Immunol (2000) 0.83
Immunoglobulin expression in diploid and polyploid interspecies hybrid of Xenopus: evidence for allelic exclusion. Eur J Immunol (1983) 0.83
The generation of antibody diversity in the turtle. J Immunol (1996) 0.81
Demographic methods to assess food insecurity: a North Korean case study. Prehosp Disaster Med (2002) 0.81
Three-dimensional structure of cat tibialis anterior motor units. Muscle Nerve (1995) 0.81
Aspergillus-related aortic thrombosis. CMAJ (1987) 0.80
IgH diversity in an individual with only one million B lymphocytes. Dev Immunol (1993) 0.79
Characterization of keratinocyte growth factor binding to heparin and dextran sulfate. Arch Biochem Biophys (1996) 0.79
Measurement of bilirubin partition coefficients in bile salt micelle/aqueous buffer solutions by micellar electrokinetic chromatography. Electrophoresis (2000) 0.79
MRI diagnosis of gliomatosis cerebri. Pediatr Neurol (1999) 0.78
Measuring CDR3 length variability in individuals during ontogeny. J Immunol Methods (1994) 0.78
Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch Neurol (1996) 0.77
Changes in lactate dehydrogenase isoenzymes associated with relapse of childhood acute lymphocytic leukemia. Pediatr Hematol Oncol (1995) 0.77
Junctional diversity in Xenopus immunoglobulin light chains. Mol Immunol (1999) 0.77
Physical map and genetic early region of the T7-related coliphage, BA14. Gene (1991) 0.76
Abbreviated junctional sequences impoverish antibody diversity in urodele amphibians. J Immunol (1997) 0.76
Neuroblastoma and fetal exposure to phenytoin in a child without dysmorphic features. Can J Neurol Sci (1992) 0.76
Clinical and laboratory diagnosis of hemostatic disorders in newborn infants. Am J Pediatr Hematol Oncol (1979) 0.75
Cystic fibrosis in a Puerto Rican female homozygous for the R1066C mutation. J Med Genet (1998) 0.75
[Effect of a 2-year ambulatory vascular sports program on walking distance in claudication patients--a controlled study]. Vasa Suppl (1991) 0.75
[Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities]. Vasa Suppl (1991) 0.75
[Global decompensated heart failure in a 21-year-old type 1 diabetic patient with marked diabetic sequelae and retarded growth and sexual development]. Internist (Berl) (1997) 0.75
Molecular identity of a sperm acrosome antigen recognized by HS-63 monoclonal antibody. J Reprod Immunol (1993) 0.75
Evaluation of a simple immunodiffusion technique for quantitation of platelet-associated immunoglobulin G in childhood immune thrombocytopenias. Am J Pediatr Hematol Oncol (1985) 0.75
Mitogenic effects of phorbol myristate acetate (PMA) on amphibian cells. Ann Inst Pasteur Immunol (1986) 0.75
An unusual behavior of brainstem ependymoma. J Child Neurol (1998) 0.75
Neutrophilic eccrine hidradenitis in acute myelomonocytic leukemia. Am J Pediatr Hematol Oncol (1987) 0.75
[Does infusion therapy in trained patients with intermittent claudication have advantages?]. Vasa Suppl (1990) 0.75
Regulation of renal sulfoglycolipid biosynthesis. Biochim Biophys Acta (1986) 0.75
Intravascular ultrasound (IVUS) in patients with peripheral arterial occlusive disease (PAOD). Vasa (1992) 0.75
[Acute effects of special water gymnastics on the venous system of patients with chronic venous insufficiency]. Vasa Suppl (1991) 0.75
[Examination of peripheral arteries with intravascular ultrasound. The informative value and limits of the method in comparison with angiography]. Vasa Suppl (1991) 0.75
[Value of intravascular ultrasound for therapy follow-up of various angioplasty procedures of peripheral arteries]. Vasa Suppl (1991) 0.75
3849 + 10 kb C --> T splicing mutation in Hispanic CF patients. Mol Genet Metab (1998) 0.75
Studies of a sperm/placenta cross-reacting antigen, STX-10. J Reprod Immunol (1993) 0.75